When prostate brachytherapy fails: a case report and discussion.
For appropriately selected brachytherapy patients, prostate-specific antigen failure is uncommon. Our patient experienced biochemical failure after 125I brachytherapy treatment for low-risk prostate adenocarcinoma. We suggest neoadjuvant/adjuvant hormonal therapy combined with pelvic external-beam radiation therapy as a reasonable salvage treatment. At the 2-year follow-up, he is apparently doing well. With limited data available, salvage management for this situation is presently investigational.
Kadoch
Cigall
C
University of California, Berkeley, California, USA.
D'Amico
Anthony V
AV
Matthews
Richard H
RH
D000230:Adenocarcinoma / Q000532:radiotherapy*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D017211:Treatment Failure
D017430:Prostate-Specific Antigen